Ironwood Historical Income Statement
IRWD Stock | USD 8.31 0.25 3.10% |
Historical analysis of Ironwood Pharmaceuticals income statement accounts such as Total Revenue of 231.7 M or Gross Profit of 224 M can show how well Ironwood Pharmaceuticals performed in making a profits. Evaluating Ironwood Pharmaceuticals income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Ironwood Pharmaceuticals's future profits or losses.
Financial Statement Analysis is much more than just reviewing and examining Ironwood Pharmaceuticals latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Ironwood Pharmaceuticals is a good buy for the upcoming year.
Ironwood |
About Ironwood Income Statement Analysis
Ironwood Pharmaceuticals Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Ironwood Pharmaceuticals shareholders. The income statement also shows Ironwood investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).
Ironwood Pharmaceuticals Income Statement Chart
Ironwood Pharmaceuticals Income Statement is one of the three primary financial statements used for reporting Ironwood's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of Ironwood Pharmaceuticals revenue and expense. Ironwood Pharmaceuticals Income Statement primarily focuses on the company's revenues and expenses during a particular period.
At present, Ironwood Pharmaceuticals' Operating Income is projected to increase significantly based on the last few years of reporting. The current year's EBIT is expected to grow to about 219.5 M, whereas Interest Expense is forecasted to decline to about 19.9 M. Add Fundamental
Depreciation And Amortization
The systematic reduction in the recorded value of an intangible asset. This includes the allocation of the cost of tangible assets to periods in which the assets are used, representing the expense related to the wear and tear, deterioration, or obsolescence of physical assets and intangible assets over their useful lives.Total Revenue
Total revenue comprises all receipts Ironwood Pharmaceuticals generated from the sale of its products or services. The total amount of income generated by the sale of goods or services related to the company's primary operations.Other Operating Expenses
Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Ironwood Pharmaceuticals. It is also known as Ironwood Pharmaceuticals overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.Operating Income
Operating Income is the amount of profit realized from Ironwood Pharmaceuticals operations after accounting for operating expenses such as cost of goods sold (COGS), wages and depreciation. Operating income takes the gross income and subtracts other operating expenses and then removes depreciation. Operating Income of Ironwood Pharmaceuticals is typically a synonym for earnings before interest and taxes (EBIT) and is also commonly referred to as operating profit or recurring profit. Earnings before interest and taxes (EBIT), representing the amount of profit a company generates from its operations.Most accounts from Ironwood Pharmaceuticals' income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Ironwood Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Ironwood Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in housing. For information on how to trade Ironwood Stock refer to our How to Trade Ironwood Stock guide.At present, Ironwood Pharmaceuticals' Operating Income is projected to increase significantly based on the last few years of reporting. The current year's EBIT is expected to grow to about 219.5 M, whereas Interest Expense is forecasted to decline to about 19.9 M.
2021 | 2022 | 2023 | 2024 (projected) | Interest Expense | 31.2M | 7.6M | 21.6M | 19.9M | Depreciation And Amortization | 682K | 9.5M | 1.6M | 1.5M |
Ironwood Pharmaceuticals income statement Correlations
Click cells to compare fundamentals
Ironwood Pharmaceuticals Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Ironwood Pharmaceuticals income statement Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Depreciation And Amortization | 297K | 16.9M | 682K | 9.5M | 1.6M | 1.5M | |
Interest Expense | 36.6M | 29.5M | 31.2M | 7.6M | 21.6M | 19.9M | |
Total Revenue | 428.4M | 389.5M | 413.8M | 410.6M | 442.7M | 231.7M | |
Gross Profit | 404.5M | 386.4M | 412.2M | 409.2M | 441.2M | 224.0M | |
Other Operating Expenses | 311.4M | 231.2M | 181.5M | 160.3M | 233.7M | 243.2M | |
Operating Income | 120.1M | 142.9M | 232.3M | 250.3M | 209.0M | 219.5M | |
Ebit | 120.1M | 142.9M | 232.3M | 250.3M | 209.0M | 219.5M | |
Research Development | 115.0M | 88.1M | 70.4M | 44.3M | 99.4M | 107.6M | |
Ebitda | 120.4M | 159.9M | 232.9M | 259.8M | 210.6M | 221.1M | |
Cost Of Revenue | 23.9M | 3.1M | 1.5M | 1.4M | 1.6M | 1.5M | |
Total Operating Expenses | 287.5M | 228.1M | 181.5M | 160.3M | 232.1M | 235.7M | |
Income Before Tax | 58.9M | 108.9M | 200.7M | 252.4M | (948.1M) | (900.7M) | |
Total Other Income Expense Net | (61.2M) | (34.1M) | (31.6M) | 2.1M | (1.2B) | (1.1B) | |
Net Income | (15.3M) | 106.2M | 528.4M | 175.1M | (1.0B) | (952.1M) | |
Income Tax Expense | 74.3M | 2.7M | (327.8M) | 77.4M | 83.5M | 87.7M | |
Selling General Administrative | 172.5M | 140.0M | 111.1M | 116.0M | 148.0M | 138.7M | |
Net Income From Continuing Ops | 58.9M | 106.2M | 528.4M | 175.1M | (980.9M) | (931.9M) | |
Non Operating Income Net Other | (24.6M) | (4.6M) | (452K) | 9.7M | 8.7M | 9.2M | |
Net Income Applicable To Common Shares | 21.5M | 106.2M | 528.4M | 175.1M | 201.3M | 211.4M | |
Non Recurring | 309K | 167.7M | 3.6M | 15.4M | 17.7M | 16.8M | |
Interest Income | 2.9M | 1.5M | 726K | 9.5M | 23.2M | 24.4M | |
Net Interest Income | (33.7M) | (28.0M) | (30.4M) | 1.9M | 8.5M | 8.9M | |
Reconciled Depreciation | 5.6M | 3.6M | 1.5M | 1.4M | 1.4M | 1.3M |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Ironwood Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in housing. For information on how to trade Ironwood Stock refer to our How to Trade Ironwood Stock guide.You can also try the Stock Screener module to find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook..
Complementary Tools for Ironwood Stock analysis
When running Ironwood Pharmaceuticals' price analysis, check to measure Ironwood Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Ironwood Pharmaceuticals is operating at the current time. Most of Ironwood Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Ironwood Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Ironwood Pharmaceuticals' price. Additionally, you may evaluate how the addition of Ironwood Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
FinTech Suite Use AI to screen and filter profitable investment opportunities | |
Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
Content Syndication Quickly integrate customizable finance content to your own investment portal | |
Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
Equity Valuation Check real value of public entities based on technical and fundamental data |
Is Ironwood Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Ironwood Pharmaceuticals. If investors know Ironwood will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Ironwood Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.69) | Earnings Share (6.45) | Revenue Per Share 2.848 | Quarterly Revenue Growth 0.097 | Return On Assets 0.1339 |
The market value of Ironwood Pharmaceuticals is measured differently than its book value, which is the value of Ironwood that is recorded on the company's balance sheet. Investors also form their own opinion of Ironwood Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Ironwood Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Ironwood Pharmaceuticals' market value can be influenced by many factors that don't directly affect Ironwood Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Ironwood Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Ironwood Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Ironwood Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.